CLDN6–CD3 Bispecific Antibody Formulation for Specific Cancer Targeting
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing CLDN therapeutics face challenges due to lack of antibody specificity for particular CLDN proteins and widespread expression of closely related family members on normal cells, making it difficult to modulate CLDN activity effectively for cancer treatment.
Innovation Solution
Development of bispecific antibodies comprising a CLDN6 binding domain and a CD3 binding domain, formulated with specific concentrations of histidine buffer, sucrose, and polysorbate-20, to enhance targeting and modulate CLDN activity in cancers.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional antibodies targeting CLDN family members are used, then broad coverage of cancer types is achieved, but specificity for particular CLDN proteins is lost due to widespread expression on normal cells
Solution Approach 1:
The patent segments the antibody targeting function by creating a bispecific antibody that separately targets CLDN6 and CD3. The CLDN6 binding domain provides cancer cell specificity while the CD3 binding domain directs the antibody to T cells, preventing off-target effects on normal cells that express CLDN family members
Solution Approach 2:
The patent introduces CD3 as an intermediary target. Instead of directly targeting CLDN6 on cancer cells (which risks off-target binding to normal cells), the bispecific antibody uses CD3 on T cells as an intermediary, bringing the immune system into the equation to selectively eliminate cancer cells expressing CLDN6
2Reliability
If monospecific anti-CLDN antibodies are used, then simplicity of design is maintained, but therapeutic efficacy is reduced due to inability to selectively target cancer cells
Solution Approach 1:
The patent merges two specific binding functions into a single bispecific antibody molecule. The CLDN6 binding domain provides cancer cell recognition while the CD3 binding domain provides T cell engagement, combining both functions in one therapeutic agent to achieve selective cancer cell targeting
Solution Approach 2:
The bispecific antibody structure provides multi-functionality: it simultaneously binds to CLDN6 on cancer cells and CD3 on T cells, effectively acting as a bridge that recruits immune cells to eliminate cancer targets while maintaining a single administerable therapeutic molecule
3Reliability
If CLDN therapeutics are developed without considering formulation stability, then development time is reduced, but product stability and shelf life are compromised
Solution Approach 1:
The patent optimizes formulation parameters including buffer composition (histidine buffer at pH 5.5-7.0), excipient concentrations (sucrose 50-500 mM, polysorbate-20 0.003-0.3% w/v), and antibody concentration ranges to achieve stable formulations that maintain therapeutic efficacy while ensuring appropriate shelf life
Data Source
AI summary
Provided for herein are pharmaceutical compositions comprising an antibody, such as a bispecific antibody that binds to Claudin 6 and CD3, and uses thereof, and methods of using the same.